Active	Status	Sponsor type	Region	Phase	Filter
9 Active 2 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wolf, Dominik
LUSPLUS, NCT05181592: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.	Recruiting	3	70	Europe	Luspatercept, Reblozyl	GWT-TUD GmbH, Celgene	Myelodysplastic Syndromes	12/24	06/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients	Recruiting	2	168	Europe, RoW	MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab	Miltenyi Biomedicine GmbH, ICON plc	Diffuse Large B-cell Lymphoma	12/24	07/27
PALINDROM, NCT06172894: PBMC-based Leukocyte Immunotherapy	Recruiting	1	12	Europe	APN401	invIOs GmbH	Advanced Solid Tumor	03/24	03/24